Institut Català de la Salut
[Tamarozzi F, Rodari P] Department of Infectious-Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy. [Salas-Coronas J, Soriano-Pérez MJ] Tropical Medicine Unit, Hospital de Poniente, El Ejido, Almería, Spain. [Bottieau E] Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium. [Salvador F, Treviño B] Unitat de Medicina Tropical i Salut Internacional Drassanes-Vall d'Hebron Hospital Universitari, Barcelona, Spain. Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-11-30T08:17:31Z
2022-11-30T08:17:31Z
2022-10
Mansonella perstans; Travel; Treatment
Mansonella perstans; Viaje; Tratamiento
Mansonella perstans; Viatge; Tractament
Background Infection with Mansonella perstans is a neglected filariasis, widely distributed in sub-Saharan Africa, characterized by an elusive clinical picture; treatment for mansonellosis is not standardized. This retrospective study aimed to describe the clinical features, treatment schemes and evolution, of a large cohort of imported cases of M. perstans infection seen in four European centres for tropical diseases. Methods Mansonella perstans infections, diagnosed by identification of blood microfilariae in migrants, expatriates and travellers, collected between 1994 and 2018, were retrospectively analysed. Data concerning demographics, clinical history and laboratory examinations at diagnosis and at follow-up time points were retrieved. Results A total of 392 patients were included in the study. Of the 281 patients for whom information on symptoms could be retrieved, 150 (53.4%) reported symptoms, abdominal pain and itching being the most frequent. Positive serology and eosinophilia were present in 84.4% and 66.1%, respectively, of those patients for whom these data were available. Concomitant parasitic infections were reported in 23.5% of patients. Treatment, administered to 325 patients (82.9%), was extremely heterogeneous between and within centres; the most commonly used regimen was mebendazole 100 mg twice a day for 1 month. A total of 256 (65.3%) patients attended a first follow-up, median 3 months (interquartile range 2–12) after the first visit; 83.1% of patients having received treatment based on mebendazole and/or doxycycline, targeting Wolbachia, became amicrofilaremic, 41.1–78.4% of whom within 12 months from single treatment. Conclusions Lack of specific symptoms, together with the inconstant positivity of parasitological and antibody-based assays in the infected population, makes the clinical suspicion and screening for mansonellosis particularly difficult. Prospective studies evaluating prevalence of infection in migrants from endemic areas, infection-specific morbidity, presence of Wolbachia endosymbionts in M. perstans populations from different geographical areas and efficacy of treatment regimens are absolutely needed to optimize the clinical management of infection.
The publication of this study was funded by Italian Ministry of Health Fondi Ricerca Corrente–L2 to IRCCS Sacro Cuore Don Calabria Hospital.
Article
Published version
English
Nematodes; Malalties parasitàries - Tractament; Agents antiparasitaris - Ús terapèutic; Malalties transmissibles; DISEASES::Parasitic Diseases::Helminthiasis::Nematode Infections::Secernentea Infections::Spirurida Infections::Filariasis::Mansonelliasis; Other subheadings::Other subheadings::Other subheadings::/drug therapy; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiparasitic Agents; Other subheadings::Other subheadings::/therapeutic use; DISEASES::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Travel-Related Illness; ENFERMEDADES::enfermedades parasitarias::helmintiasis::infecciones por nematodos::infecciones por Secernentea::infecciones por Spirurida::filariasis::mansoneliasis; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antiparasitarios; Otros calificadores::Otros calificadores::/uso terapéutico; ENFERMEDADES::afecciones patológicas, signos y síntomas::signos y síntomas::enfermedades relacionadas con los viajes
Oxford University Press
Journal of Travel Medicine;29(7)
https://doi.org/10.1093/jtm/taac048
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
Articles científics - HVH [3436]